Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
e-Edition
News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Place an Ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
POLBF
)
0.1150
UNCHANGED
Last Price
Updated: 9:30 AM EST, Feb 7, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.1150
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1150
Today's Range
0.1150 - 0.1150
52wk Range
0.1001 - 0.1050
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Poolbeg Pharma PLC Announces Board Appointment
May 24, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Results of Annual General Meeting
May 11, 2023
Via
ACCESSWIRE
Performance
YTD
+14.89%
+14.89%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+57.53%
+57.53%
1 Year
+43.93%
+43.93%
More News
Read More
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
April 12, 2023
Via
ACCESSWIRE
Poolbeg Pharma "in a very healthy cash position" after first full year of operations
March 30, 2023
Via
News Direct
Poolbeg Pharma "in a very healthy cash position" after first full year of operations
March 30, 2023
Via
TheNewswire.com
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022
March 30, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Strategic Expansion of POLB 001 into Oncology
January 16, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial
January 09, 2023
Via
ACCESSWIRE
Poolbeg Identifies Novel RSV Drug Candidates
December 21, 2022
Via
ACCESSWIRE
Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma
March 09, 2023
Via
News Direct
Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma
March 09, 2023
Via
TheNewswire.com
Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data
March 02, 2023
Via
News Direct
Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data
March 02, 2023
Via
TheNewswire.com
Poolbeg Pharma "really open" to different types of deal for POLB 001
March 01, 2023
Via
News Direct
Poolbeg Pharma PLC Announces Metabolic Diseases Oral Delivery Licence Signed
December 14, 2022
Via
ACCESSWIRE
Poolbeg Pharma PLC - POLB 001 LPS Human Challenge Trial Completed
December 12, 2022
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Influenza AI model build completed
November 29, 2022
Via
ACCESSWIRE
Poolbeg-led Consortium Awarded EUR 2.3m Grant
November 15, 2022
Via
ACCESSWIRE
Poolbeg Pharma "really open" to different types of deal for POLB 001
March 01, 2023
Via
TheNewswire.com
Poolbeg Pharma announces expansion of POLB 001 into oncology
January 18, 2023
Via
News Direct
Topics
Intellectual Property
Exposures
Intellectual Property
Poolbeg Pharma announces expansion of POLB 001 into oncology
January 18, 2023
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Poolbeg Pharma upbeat on preliminary influenza drug results
January 09, 2023
Via
News Direct
Poolbeg Pharma upbeat on preliminary influenza drug results
January 09, 2023
Via
TheNewswire.com
Poolbeg Pharma PLC Announces AI Programme Yields Novel RSV Drug Targets
November 08, 2022
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Capital Markets Day
November 17, 2022
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
